IR@PKUHSC  > 北京大学第一临床医学院  > 大内科
学科主题临床医学
Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study
Wong, BCY1; Wang, WH1; Wong, WM1; Lau, GKK1; Fung, FMY1; Kung, NNS1; Chu, KM1; Lai, KC1; Hu, WHC1; Hu, FL1; Liu, XG1; Chan, CK1; Yuen, MF1; Hui, WM1; Lam, SK1
刊名ALIMENTARY PHARMACOLOGY & THERAPEUTICS
2001-06-01
15期:6页:843-849
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Gastroenterology & Hepatology ; Pharmacology & Pharmacy
研究领域[WOS]Gastroenterology & Hepatology ; Pharmacology & Pharmacy
关键词[WOS]WEEK TRIPLE THERAPY ; ROUTINE TREATMENT ; INFECTION ; CLARITHROMYCIN ; METRONIDAZOLE ; ERADICATION ; TRIAL ; CURE ; OMEPRAZOLE ; 2-DAY
英文摘要

Aim: To compare the efficacy and tolerability of a 3-day quadruple therapy with a standard 7-day triple therapy in eradicating Helicobacter pylori infection and healing duodenal ulcers.

Methods: Patients with H. pylori-positive duodenal ulcers were randomized to receive either lansoprazole 30 mg, clarithromycin 500 mg, and metronidazole 400 mg twice daily for 7 days (LCM-7) or lansoprazole 30 mg, clarithromycin 500 mg, metronidazole 400 mg, and bismuth subcitrate 240 mg twice daily for 3 days (LCMB-3). No pre- or post-treatment acid suppression was used. Follow-up endoscopy was performed at week 6.

Results: A total of 118 patients were recruited. Sixty patients in the LCM-7 group and 53 patients in the LCMB-3 group returned for endoscopy. Intention-to-treat eradication rates were 87% and 86% (P=0.94) and per protocol eradication rates were 87% and 94% (P=0.29) in the LCM-7 and LCMB-3 groups, respectively. Per protocol and intention-to-treat ulcer healing rates were 98% and 98% in LCM-7 and 100% and 91% in LCMB-3, respectively. There were no significant differences in efficacy in relation to the initial metronidazole and clarithromycin susceptibility. Significant reduction in the duration of side-effects was found in the LCMB-3 group.

Conclusion: The 3-day quadruple therapy is highly effective, better tolerated and can be considered as a first-line therapy in duodenal ulcer management.

语种英语
WOS记录号WOS:000168747600011
引用统计
被引频次:11[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/51979
专题北京大学第一临床医学院_大内科
作者单位1.United Christian Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
2.Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
3.Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China
4.Beijing Med Univ, Teaching Hosp 1, Dept Internal Med, Beijing, Peoples R China
推荐引用方式
GB/T 7714
Wong, BCY,Wang, WH,Wong, WM,et al. Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study[J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS,2001,15(6):843-849.
APA Wong, BCY.,Wang, WH.,Wong, WM.,Lau, GKK.,Fung, FMY.,...&Lam, SK.(2001).Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study.ALIMENTARY PHARMACOLOGY & THERAPEUTICS,15(6),843-849.
MLA Wong, BCY,et al."Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study".ALIMENTARY PHARMACOLOGY & THERAPEUTICS 15.6(2001):843-849.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wong, BCY]的文章
[Wang, WH]的文章
[Wong, WM]的文章
百度学术
百度学术中相似的文章
[Wong, BCY]的文章
[Wang, WH]的文章
[Wong, WM]的文章
必应学术
必应学术中相似的文章
[Wong, BCY]的文章
[Wang, WH]的文章
[Wong, WM]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。